Warsaw - Delayed Quote PLN
Celon Pharma S.A. (CLN.WA)
As of 2:22 PM GMT+1. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in PLN.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Maciej Wieczorek Ph.D. | CEO & President of Management Board | -- | -- | -- |
| Bartosz Szalek | CFO & Member of the Management Board | 246.45k | -- | -- |
Celon Pharma S.A.
- Sector:?
- Healthcare
- Industry:? Drug Manufacturers - Specialty & Generic
- Full Time Employees:?
- 566
Description
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.
Corporate Governance
Celon Pharma S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 20, 2024 at 10:59 AM UTC
Celon Pharma S.A. Earnings Date
Recent Events
June 27, 2024 at 12:00 AM UTC
Ex-Dividend Date